Treat-to-target in Rheumatoid Arthritis: A Quality Improvement Trial.
We sought to integrate a treat-to-target (TTT) approach for rheumatoid arthritis (RA) through routine electronic collection of patient-reported disease activity scores (RAPID3) and a multidisciplinary learning collaborative for rheumatologists, using a quality improvement approach. RA patients completed a patient-reported outcome, the RAPID3, at check-in. Nine rheumatologists and their patients were allocated to a learning collaborative intervention group focused on TTT and 13 to control. The primary outcome was documentation of a TTT implementation score: 1) disease activity score, 2) disease activity score used in the medication change decision, 3) presence of treatment target, and 4) indication of shared decision-making. Primary analysis of patient-visits with medication changes was conducted using an interrupted time-series analysis. We studied 554 individual rheumatology patients with 709 patient- visits. TTT implementation scores among intervention rheumatologists (44.6 +/- 1.63%) were 12.4% higher than the control group (32.2% +/- 1.50, p <0.0001). We observed differences in TTT implementation score components, comparing intervention to control rheumatologists: disease activity score present 77.2% versus 68.0% (p=0.02); disease activity score used in decision medication change decision 45.2% versus 30.0% (p < 0.01); treatment target 9.0% versus 0.4% (p < 0.01); and shared decision-making 46.9% versus 30.0% (p <0.01). Secondary analysis of patient-visits with high RAPID3 scores found that medication changes were 54% less likely in the intervention versus control group (OR=0.46, 95% CI 0.27-0.79, p=0.005). This non-randomized, interrupted time-series trial demonstrated a modest but significant impact of an LC intervention on rheumatologist documentation of TTT in RA.